drugset / Trial / NCT04972656
Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension
Unknown
420 enrolled
Nanjing First Hospital, Nanjing Medical University
Tianjin Medical University General Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
An Investigator initiated trial (IIT) using a prospective, randomized, double-blind, parallel group, placebo-controlled, clinical study design.
Timeline
- Start
- 2022-09-05
- Primary completion
- 2025-12-30
- Completion
- 2026-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ambrisentan | Small molecule | 5 mg | Oral |
| Subject | Ambrisentan | Small molecule | 10 mg | Oral |